JP2006520746A - リン脂質を含む免疫原性組成物 - Google Patents

リン脂質を含む免疫原性組成物 Download PDF

Info

Publication number
JP2006520746A
JP2006520746A JP2004565756A JP2004565756A JP2006520746A JP 2006520746 A JP2006520746 A JP 2006520746A JP 2004565756 A JP2004565756 A JP 2004565756A JP 2004565756 A JP2004565756 A JP 2004565756A JP 2006520746 A JP2006520746 A JP 2006520746A
Authority
JP
Japan
Prior art keywords
immunogenic composition
alkyl
composition according
group
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004565756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520746A5 (https=
Inventor
デレック オヘーガン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2006520746A publication Critical patent/JP2006520746A/ja
Publication of JP2006520746A5 publication Critical patent/JP2006520746A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004565756A 2002-12-27 2003-12-29 リン脂質を含む免疫原性組成物 Withdrawn JP2006520746A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43691902P 2002-12-27 2002-12-27
US51307503P 2003-10-21 2003-10-21
PCT/US2003/041412 WO2004060396A2 (en) 2002-12-27 2003-12-29 Immunogenic compositions containing phospholpid
US10/748,117 US8034378B2 (en) 2002-12-27 2003-12-29 Immunogenic compositions containing phospholipid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010141085A Division JP2010202669A (ja) 2002-12-27 2010-06-21 リン脂質を含む免疫原性組成物

Publications (2)

Publication Number Publication Date
JP2006520746A true JP2006520746A (ja) 2006-09-14
JP2006520746A5 JP2006520746A5 (https=) 2007-02-08

Family

ID=33135960

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004565756A Withdrawn JP2006520746A (ja) 2002-12-27 2003-12-29 リン脂質を含む免疫原性組成物
JP2010141085A Withdrawn JP2010202669A (ja) 2002-12-27 2010-06-21 リン脂質を含む免疫原性組成物
JP2014023426A Pending JP2014080442A (ja) 2002-12-27 2014-02-10 リン脂質を含む免疫原性組成物
JP2016063453A Pending JP2016117774A (ja) 2002-12-27 2016-03-28 リン脂質を含む免疫原性組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2010141085A Withdrawn JP2010202669A (ja) 2002-12-27 2010-06-21 リン脂質を含む免疫原性組成物
JP2014023426A Pending JP2014080442A (ja) 2002-12-27 2014-02-10 リン脂質を含む免疫原性組成物
JP2016063453A Pending JP2016117774A (ja) 2002-12-27 2016-03-28 リン脂質を含む免疫原性組成物

Country Status (6)

Country Link
US (2) US8034378B2 (https=)
EP (2) EP2263687B1 (https=)
JP (4) JP2006520746A (https=)
AU (1) AU2003299994A1 (https=)
CA (1) CA2511512C (https=)
WO (1) WO2004060396A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520646A (ja) * 2013-06-09 2016-07-14 エフラナット リミテッド Ｇｃ−マクロファージ活性化因子を含む組成物およびその使用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
AU2003299994A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
EP2295036A2 (en) 2004-12-10 2011-03-16 Talima Therapeutics, Inc. Liquid compositions and methods for treating conditions of the nail unit
WO2006078059A1 (ja) 2005-01-19 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. 希釈用乳化組成物および癌ワクチン組成物
AU2006220835B2 (en) 2005-03-04 2012-01-19 Dynavax Technologies Corporation Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2008051245A2 (en) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8628701B2 (en) * 2006-10-31 2014-01-14 Xavier University Of Louisiana Method of micro-encapsulation
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
ES2524699T3 (es) 2008-06-05 2014-12-11 Immunovaccine Technologies Inc. Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
EP2496255A4 (en) * 2009-11-05 2014-03-26 Mercia Pharma Inc ADJUVATED INFLUENZA VACCINE IN NANOPARTICLE FORM
ES2585286T3 (es) * 2010-02-27 2016-10-04 Stellenbosch University Composiciones de tensioactivo que comprenden complejos polipéptidos
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
JP6240077B2 (ja) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US10772946B2 (en) 2015-10-13 2020-09-15 Sanofi Pasteur Immunogenic compositions against S. aureus
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
FR3058647B1 (fr) 2016-11-14 2018-12-07 Mathym Suspension colloidale de nanoparticules de fluorure d'element alcalino-terreux fonctionnalisees
CN110958887B (zh) 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
KR20250006307A (ko) 2017-09-13 2025-01-10 사노피 파스퇴르 인간 시토메갈로바이러스 면역원성 조성물
US20220273824A1 (en) * 2019-08-07 2022-09-01 The Regents Of The University Of California Cell penetrating peptide functionalized perfluorocarbon nanoemulsion compositions and methods for imaging cell populations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
JP2002535411A (ja) * 1999-02-01 2002-10-22 エーザイ株式会社 免疫アジュバント化合物
JP2002539237A (ja) * 1999-03-24 2002-11-19 イギリス国 粒子を基本としたワクチン組成物

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800457A (en) 1953-06-30 1957-07-23 Ncr Co Oil-containing microscopic capsules and method of making them
NL134977C (https=) 1962-07-11
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5324513A (en) 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5098704A (en) 1984-06-18 1992-03-24 Chiron Corporation Hepatitis surface antigen particle vaccine
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ES2061500T5 (es) 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR0185373B1 (ko) 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
DK0398748T3 (da) 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
FI925835A0 (fi) * 1990-06-29 1992-12-22 Chiron Corp Vacciner innehaollande liposomer
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
PT991403E (pt) 1997-01-30 2003-08-29 Chiron Corp Uso de microparticulas com antigenio adsorvido para estimular respostas imunes
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6943236B2 (en) * 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) * 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US7541020B2 (en) * 1997-05-08 2009-06-02 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
WO1998055495A2 (en) 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
KR20010032336A (ko) 1997-11-21 2001-04-16 브랑디 빠스깔 클라미디아 뉴모니아 게놈 서열과 폴리펩티드, 이의 단편및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US6824793B1 (en) * 1998-06-01 2004-11-30 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
AU763975B2 (en) 1998-07-29 2003-08-07 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbent surfaces, methods of making same, and uses thereof
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US6465633B1 (en) * 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
EP1180031A4 (en) * 1999-04-26 2004-04-07 Univ Emory NOSCAPIN DERIVATIVES FOR USE AS ADJUVANT COMPOSITIONS AND METHODS OF USE THEREOF
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
CZ20021043A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
JP5597335B2 (ja) 1999-11-19 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 樹状細胞の微粒子ベースのトランスフェクションおよび活性化
JP2004500366A (ja) * 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること
US7772196B2 (en) * 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7785625B2 (en) * 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1299087A1 (en) 2000-07-07 2003-04-09 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
MXPA03002640A (es) * 2000-09-28 2003-06-19 Chiron Corp Microparticulas para la distribucion de acidos nucleicos heterologos.
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CN100354297C (zh) 2001-10-03 2007-12-12 希龙公司 辅助的脑膜炎球菌组合物
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
AU2003299994A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
KR100720213B1 (ko) * 2003-04-04 2007-05-21 화이자 프로덕츠 인코포레이티드 미세 유동화된 수중 유적형 유화액 및 백신 조성물
US7731967B2 (en) * 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1631264B8 (en) * 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US7615530B2 (en) * 2003-08-29 2009-11-10 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
WO2007030955A1 (de) * 2005-09-15 2007-03-22 Tuboly Ag Vorrichtung und verfahren zum wickeln von elektrischen spulen
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
US8974986B2 (en) 2007-07-06 2015-03-10 M. Technique Co., Ltd. Method for producing metal-supported carbon, method for producing crystals consisting of fullerene molecules and fullerene nanowhisker/nanofiber nanotubes, and apparatus for producing the same
AT514720B1 (de) 2013-08-30 2016-03-15 Blum Gmbh Julius Stellvorrichtung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535411A (ja) * 1999-02-01 2002-10-22 エーザイ株式会社 免疫アジュバント化合物
JP2002539237A (ja) * 1999-03-24 2002-11-19 イギリス国 粒子を基本としたワクチン組成物
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520646A (ja) * 2013-06-09 2016-07-14 エフラナット リミテッド Ｇｃ−マクロファージ活性化因子を含む組成物およびその使用

Also Published As

Publication number Publication date
WO2004060396A2 (en) 2004-07-22
CA2511512A1 (en) 2004-07-22
US20120114692A1 (en) 2012-05-10
CA2511512C (en) 2013-10-29
EP2263687B1 (en) 2015-03-25
JP2014080442A (ja) 2014-05-08
US20040202669A1 (en) 2004-10-14
EP1585542B1 (en) 2012-06-13
JP2016117774A (ja) 2016-06-30
WO2004060396A3 (en) 2005-04-28
AU2003299994A1 (en) 2004-07-29
JP2010202669A (ja) 2010-09-16
EP1585542A2 (en) 2005-10-19
US8034378B2 (en) 2011-10-11
US8541023B2 (en) 2013-09-24
EP2263687A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
JP2016117774A (ja) リン脂質を含む免疫原性組成物
JP5832485B2 (ja) 吸着したポリペプチド含有分子を有する微粒子
JP2006520746A5 (https=)
EP1322292B1 (en) Microparticle compositions and methods for the manufacture thereof
JP5557415B2 (ja) 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
AU2001294898A1 (en) Microparticle compositions and methods for the manufacture thereof
US20150072016A1 (en) Microparticles with adsorbed polynucleotide-containing species
ES2387565T3 (es) Composiciones inmunogénicas que contienen fosfolípidos

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110216

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120525

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120629

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140205